[
  {
    "ts": null,
    "headline": "Why Novo Nordisk Stock Flew Higher on Friday",
    "summary": "It looked good next to a company that has been stealing its thunder lately.",
    "url": "https://finnhub.io/api/news?id=33914b75260a0a61fcc797eeb10dd2c8d2645ff58886cda599d7272c03a70ebb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754694014,
      "headline": "Why Novo Nordisk Stock Flew Higher on Friday",
      "id": 136276201,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "It looked good next to a company that has been stealing its thunder lately.",
      "url": "https://finnhub.io/api/news?id=33914b75260a0a61fcc797eeb10dd2c8d2645ff58886cda599d7272c03a70ebb"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly Stock Sank 18% This Week",
    "summary": "The drugmaker is in a 35% drawdown.",
    "url": "https://finnhub.io/api/news?id=5e01830a505cd92b13fab2f58a83e4e1a09f16864763249ac5dfe52bef6a8b55",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754688346,
      "headline": "Why Eli Lilly Stock Sank 18% This Week",
      "id": 136276202,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drugmaker is in a 35% drawdown.",
      "url": "https://finnhub.io/api/news?id=5e01830a505cd92b13fab2f58a83e4e1a09f16864763249ac5dfe52bef6a8b55"
    }
  },
  {
    "ts": null,
    "headline": "GLP-1 race heats up: Where Eli Lilly stands after weak trial data",
    "summary": "Eli Lilly's (LLY) recent earnings and GLP-1 trial results shook the biopharma market this week. Courtney Breen, Bernstein senior analyst of US biopharmaceuticals, breaks down what the trial data means for Eli Lilly and the wider pharma space. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=b244d5e1337aefeebbc1725d0929d9e8ffa9aa963652b721995890ad6a7a4b97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754687299,
      "headline": "GLP-1 race heats up: Where Eli Lilly stands after weak trial data",
      "id": 136276203,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's (LLY) recent earnings and GLP-1 trial results shook the biopharma market this week. Courtney Breen, Bernstein senior analyst of US biopharmaceuticals, breaks down what the trial data means for Eli Lilly and the wider pharma space. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=b244d5e1337aefeebbc1725d0929d9e8ffa9aa963652b721995890ad6a7a4b97"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on Roche Holding, Novo Nordisk, Eli Lilly and more in the latest Market Talks covering Health Care.",
    "url": "https://finnhub.io/api/news?id=06b61d8eba26278fd7f91453c6cd4221bd145ae6324cf281455d65ea230b71db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754654220,
      "headline": "Health Care Roundup: Market Talk",
      "id": 136271003,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Find insight on Roche Holding, Novo Nordisk, Eli Lilly and more in the latest Market Talks covering Health Care.",
      "url": "https://finnhub.io/api/news?id=06b61d8eba26278fd7f91453c6cd4221bd145ae6324cf281455d65ea230b71db"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Advances on Week Amid Gains in Information Technology, Consumer Discretionary",
    "summary": "The Standard & Poor's 500 index rose 2.4% this week, led by technology and consumer discretionary st",
    "url": "https://finnhub.io/api/news?id=b5b30efd5aa22bdc85bf8be8bb2bef2ed2140294321be19c05eb9a55c120d82f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754686011,
      "headline": "S&P 500 Advances on Week Amid Gains in Information Technology, Consumer Discretionary",
      "id": 136276095,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Standard & Poor's 500 index rose 2.4% this week, led by technology and consumer discretionary st",
      "url": "https://finnhub.io/api/news?id=b5b30efd5aa22bdc85bf8be8bb2bef2ed2140294321be19c05eb9a55c120d82f"
    }
  },
  {
    "ts": null,
    "headline": "Investing.com’s stocks of the week",
    "summary": "Investing.com -- U.S. equities rose this week, with investors reacting to a mix of corporate earnings reports and broader economic developments.",
    "url": "https://finnhub.io/api/news?id=7b2f9a33ab647d2153181cfa4cae59811a71d70ed64776e1fd9bc0329da45a49",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754677725,
      "headline": "Investing.com’s stocks of the week",
      "id": 136290066,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- U.S. equities rose this week, with investors reacting to a mix of corporate earnings reports and broader economic developments.",
      "url": "https://finnhub.io/api/news?id=7b2f9a33ab647d2153181cfa4cae59811a71d70ed64776e1fd9bc0329da45a49"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of August 10",
    "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full list for the week of August 10, 2025 -- here on Seeking Alpha.",
    "url": "https://finnhub.io/api/news?id=d3328f7322da5e3893bf572815a85939fa978cabae6f64d3ced8fdd259c3dc94",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754676459,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of August 10",
      "id": 136273781,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full list for the week of August 10, 2025 -- here on Seeking Alpha.",
      "url": "https://finnhub.io/api/news?id=d3328f7322da5e3893bf572815a85939fa978cabae6f64d3ced8fdd259c3dc94"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Sees Revenue Surge With Innovative Treatments And Raised Earnings Guidance",
    "summary": "Eli Lilly (LLY) has recently launched SenderraCare+, a digital solution paired with its biologic treatment EBGLYSS, and announced positive outcomes from a Phase 3 trial for the weight management drug orforglipron. Despite these advancements, the company's stock fell 13% in the last quarter. The sharp price drop contrasts with a generally rising market environment, marked by gains in major indexes and record highs for gold. This decline could be weighed by legal challenges, despite robust...",
    "url": "https://finnhub.io/api/news?id=1d48adf9ff46d725a5b117c24e239ca256935768f2e8a093cfc3fcc0fab33861",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754674768,
      "headline": "Eli Lilly (LLY) Sees Revenue Surge With Innovative Treatments And Raised Earnings Guidance",
      "id": 136276206,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) has recently launched SenderraCare+, a digital solution paired with its biologic treatment EBGLYSS, and announced positive outcomes from a Phase 3 trial for the weight management drug orforglipron. Despite these advancements, the company's stock fell 13% in the last quarter. The sharp price drop contrasts with a generally rising market environment, marked by gains in major indexes and record highs for gold. This decline could be weighed by legal challenges, despite robust...",
      "url": "https://finnhub.io/api/news?id=1d48adf9ff46d725a5b117c24e239ca256935768f2e8a093cfc3fcc0fab33861"
    }
  },
  {
    "ts": null,
    "headline": "This Unusually Active Wayfair Put Option Explains a Lot About the Current Markets",
    "summary": "Wayfair had three unusually active options in Thursday trading. One of them was in the top 20. While you can debate whether they were bullish or bearish bets, you can’t ignore what it says about the current state of the markets.",
    "url": "https://finnhub.io/api/news?id=c0e6bd63777fdcb3b333fe712bba73ae93ba041d6c1d20d38c19e34b4b832329",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754674202,
      "headline": "This Unusually Active Wayfair Put Option Explains a Lot About the Current Markets",
      "id": 136276207,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Wayfair had three unusually active options in Thursday trading. One of them was in the top 20. While you can debate whether they were bullish or bearish bets, you can’t ignore what it says about the current state of the markets.",
      "url": "https://finnhub.io/api/news?id=c0e6bd63777fdcb3b333fe712bba73ae93ba041d6c1d20d38c19e34b4b832329"
    }
  },
  {
    "ts": null,
    "headline": "Did Eli Lilly Stock Just Have Its Novo Nordisk Moment?",
    "summary": "Many analysts trimmed price targets but remained bullish on Eli Lilly following Thursday’s stock selloff.",
    "url": "https://finnhub.io/api/news?id=a8f61a4b5eba17464ffca2ad77a6d5313dc8c5fc3744419113f515f4e13fb02b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754669940,
      "headline": "Did Eli Lilly Stock Just Have Its Novo Nordisk Moment?",
      "id": 136276208,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Many analysts trimmed price targets but remained bullish on Eli Lilly following Thursday’s stock selloff.",
      "url": "https://finnhub.io/api/news?id=a8f61a4b5eba17464ffca2ad77a6d5313dc8c5fc3744419113f515f4e13fb02b"
    }
  },
  {
    "ts": null,
    "headline": "Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization",
    "summary": "Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization Novel, oral candidate with first-in-class potential progresses successfully through Lilly’s Phase 1 clinical trial in healthy volunteers Sitryx reintegrates SYX-1042 into portfolio of novel small molecule candidates targeting major autoimmune indications with high unmet need Oxford, UK – 8 August 2025 – Sitryx Therapeutics (“the Company”), a clinica",
    "url": "https://finnhub.io/api/news?id=3911930ff1921c7ae266eb58595310cffa0eee177b75b765e3e4cefceb404dca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754668800,
      "headline": "Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization",
      "id": 136276209,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization Novel, oral candidate with first-in-class potential progresses successfully through Lilly’s Phase 1 clinical trial in healthy volunteers Sitryx reintegrates SYX-1042 into portfolio of novel small molecule candidates targeting major autoimmune indications with high unmet need Oxford, UK – 8 August 2025 – Sitryx Therapeutics (“the Company”), a clinica",
      "url": "https://finnhub.io/api/news?id=3911930ff1921c7ae266eb58595310cffa0eee177b75b765e3e4cefceb404dca"
    }
  },
  {
    "ts": null,
    "headline": "Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y",
    "summary": "NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.",
    "url": "https://finnhub.io/api/news?id=d60f65b6a2ed27a70aa5950cc1f4c12effc38983a2ed379f0c8409e82fd07667",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754667900,
      "headline": "Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y",
      "id": 136276210,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.",
      "url": "https://finnhub.io/api/news?id=d60f65b6a2ed27a70aa5950cc1f4c12effc38983a2ed379f0c8409e82fd07667"
    }
  },
  {
    "ts": null,
    "headline": "ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data",
    "summary": "LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.",
    "url": "https://finnhub.io/api/news?id=e220c897976afcbb7c1d13a83ee653d202d8adceef8f98a68521a95c1e93317b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754665200,
      "headline": "ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data",
      "id": 136271016,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.",
      "url": "https://finnhub.io/api/news?id=e220c897976afcbb7c1d13a83ee653d202d8adceef8f98a68521a95c1e93317b"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market News for Aug 8, 2025",
    "summary": "U.S. stocks ended mixed on Thursday, with the Dow and the S&P 500 giving up their gains, as investors assessed President Donald Trump's plans to impose hefty tariffs on chip imports and digested the latest batch of corporate earnings.",
    "url": "https://finnhub.io/api/news?id=1dbecfbd5c1759aabd19de31dbc713e912c1778d10b913b71f691060474c15da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754659320,
      "headline": "Stock Market News for Aug 8, 2025",
      "id": 136276212,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "U.S. stocks ended mixed on Thursday, with the Dow and the S&P 500 giving up their gains, as investors assessed President Donald Trump's plans to impose hefty tariffs on chip imports and digested the latest batch of corporate earnings.",
      "url": "https://finnhub.io/api/news?id=1dbecfbd5c1759aabd19de31dbc713e912c1778d10b913b71f691060474c15da"
    }
  },
  {
    "ts": null,
    "headline": "Tariffs Be Damned. Stocks Flirt With a New Record High.",
    "summary": "Tariffs Be Damned. Stocks Flirt With a New Record High.",
    "url": "https://finnhub.io/api/news?id=605a210f5f4851711d50b836243607b7cde31069c371bcc16fed56f77cced7cf",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754659020,
      "headline": "Tariffs Be Damned. Stocks Flirt With a New Record High.",
      "id": 136296160,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Tariffs Be Damned. Stocks Flirt With a New Record High.",
      "url": "https://finnhub.io/api/news?id=605a210f5f4851711d50b836243607b7cde31069c371bcc16fed56f77cced7cf"
    }
  },
  {
    "ts": null,
    "headline": "Does This $856 Million Investment Make Eli Lilly Stock a Buy?",
    "summary": "The drugmaker continues to grab headlines for all the right reasons.",
    "url": "https://finnhub.io/api/news?id=63f1d223743df73322e5c8cfab8d9292bf62ed7ee912d683986d9fb3371a53a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754658000,
      "headline": "Does This $856 Million Investment Make Eli Lilly Stock a Buy?",
      "id": 136266264,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drugmaker continues to grab headlines for all the right reasons.",
      "url": "https://finnhub.io/api/news?id=63f1d223743df73322e5c8cfab8d9292bf62ed7ee912d683986d9fb3371a53a0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?",
    "summary": "Eli Lilly has normally been a market-beating stock, but not this year.",
    "url": "https://finnhub.io/api/news?id=f852275f59ecf4c4c20bccf6fa0e020ef87b706e7cb49391a60455e76515c66d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754657220,
      "headline": "Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?",
      "id": 136266265,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly has normally been a market-beating stock, but not this year.",
      "url": "https://finnhub.io/api/news?id=f852275f59ecf4c4c20bccf6fa0e020ef87b706e7cb49391a60455e76515c66d"
    }
  },
  {
    "ts": null,
    "headline": "Elevating Patient Care: Senderra Specialty Pharmacy Adds EBGLYSS™ (lebrikizumab-lbkz), Lilly's First-Line Biologic Treatment for Moderate-to-Severe Atopic Dermatitis, to SenderraCare+ for a Streamlined, Empowering Digital Patient Experience",
    "summary": "Senderra Specialty Pharmacy announced today the addition of EBGLYSS, Lilly's first-line biologic treatment for moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg, who are not well controlled with prescription topical therapies, or who cannot use topical therapies to SenderraCare+. This innovative digital solution provides patients with a seamless, interactive patient journey in real-time, including status updates regarding thei",
    "url": "https://finnhub.io/api/news?id=59b40d6281e211e1b1454652a8891c1841478bd77787e5f4e8b4e25fc8d806bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754656800,
      "headline": "Elevating Patient Care: Senderra Specialty Pharmacy Adds EBGLYSS™ (lebrikizumab-lbkz), Lilly's First-Line Biologic Treatment for Moderate-to-Severe Atopic Dermatitis, to SenderraCare+ for a Streamlined, Empowering Digital Patient Experience",
      "id": 136266266,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Senderra Specialty Pharmacy announced today the addition of EBGLYSS, Lilly's first-line biologic treatment for moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg, who are not well controlled with prescription topical therapies, or who cannot use topical therapies to SenderraCare+. This innovative digital solution provides patients with a seamless, interactive patient journey in real-time, including status updates regarding thei",
      "url": "https://finnhub.io/api/news?id=59b40d6281e211e1b1454652a8891c1841478bd77787e5f4e8b4e25fc8d806bb"
    }
  },
  {
    "ts": null,
    "headline": "CATL, Novo Nordisk, SoftBank: Global Stocks in Focus",
    "summary": "↗️ Novo Nordisk (NVO): Shares rose for a second day, in a rally sparked by rival Eli Lilly (LLY) reporting less-than-stellar trial results for an anti-obesity pill. ↗️ CATL (HK:3750): The Chinese battery maker will supply GM (GM) with batteries until the automaker and partner LG Energy Solution (KR:373220) can increase U.",
    "url": "https://finnhub.io/api/news?id=21089219aac4b2995063844e84af63c813152c1ac82e87af92d800f086f799b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754653826,
      "headline": "CATL, Novo Nordisk, SoftBank: Global Stocks in Focus",
      "id": 136267442,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "↗️ Novo Nordisk (NVO): Shares rose for a second day, in a rally sparked by rival Eli Lilly (LLY) reporting less-than-stellar trial results for an anti-obesity pill. ↗️ CATL (HK:3750): The Chinese battery maker will supply GM (GM) with batteries until the automaker and partner LG Energy Solution (KR:373220) can increase U.",
      "url": "https://finnhub.io/api/news?id=21089219aac4b2995063844e84af63c813152c1ac82e87af92d800f086f799b7"
    }
  },
  {
    "ts": null,
    "headline": "Global Stocks in Focus: SoftBank, Novo Nordisk, CATL",
    "summary": "↗️ SoftBank Group (JP:9984): The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its tech-funds business as it made bolder AI bets. Shares jumped 10% in Tokyo. ↗️ Novo Nordisk (NVO): Shares rose for a second day in Denmark, in a rally sparked by rival Eli Lilly reporting less-than-stellar trial results for an experimental anti-obesity pill.",
    "url": "https://finnhub.io/api/news?id=b977a665e803ca388802a33f513645874ebbdead0d6efeddefede38bf98a0f23",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754653826,
      "headline": "Global Stocks in Focus: SoftBank, Novo Nordisk, CATL",
      "id": 136266267,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "↗️ SoftBank Group (JP:9984): The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its tech-funds business as it made bolder AI bets. Shares jumped 10% in Tokyo. ↗️ Novo Nordisk (NVO): Shares rose for a second day in Denmark, in a rally sparked by rival Eli Lilly reporting less-than-stellar trial results for an experimental anti-obesity pill.",
      "url": "https://finnhub.io/api/news?id=b977a665e803ca388802a33f513645874ebbdead0d6efeddefede38bf98a0f23"
    }
  },
  {
    "ts": null,
    "headline": "Morning Bid: Trump Fed forms, Tech hits high",
    "summary": "The S&P 500 may have stalled on Thursday, but the Nasdaq hit a new high, as a week of positive earnings surprises and rising Fed easing expectations overshadowed tariff worries and a few isolated stock flubs.  Tech excitement continues to push up all major index futures ahead of Friday's bell.  * The stock stumbles on Thursday included an outsize 14% earnings-day hit to pharma giant Eli Lilly after a disappointing drug trial and a 3% drop in Intel after Trump demanded the resignation of its CEO due to Chinese links.",
    "url": "https://finnhub.io/api/news?id=5ba529a69ed61ab94e8af3c20cc3714ff74dfff14ef278849e5ccbe35937dcc8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754649664,
      "headline": "Morning Bid: Trump Fed forms, Tech hits high",
      "id": 136266268,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The S&P 500 may have stalled on Thursday, but the Nasdaq hit a new high, as a week of positive earnings surprises and rising Fed easing expectations overshadowed tariff worries and a few isolated stock flubs.  Tech excitement continues to push up all major index futures ahead of Friday's bell.  * The stock stumbles on Thursday included an outsize 14% earnings-day hit to pharma giant Eli Lilly after a disappointing drug trial and a 3% drop in Intel after Trump demanded the resignation of its CEO due to Chinese links.",
      "url": "https://finnhub.io/api/news?id=5ba529a69ed61ab94e8af3c20cc3714ff74dfff14ef278849e5ccbe35937dcc8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s Miracle Weight Loss Pill May Not Be Miraculous Enough",
    "summary": "Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street estimates.",
    "url": "https://finnhub.io/api/news?id=6e167b50c0e58b76f28a56e01b156c4b39672d51621d66bcfca631e52b5de55a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754649000,
      "headline": "Eli Lilly’s Miracle Weight Loss Pill May Not Be Miraculous Enough",
      "id": 136271019,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street estimates.",
      "url": "https://finnhub.io/api/news?id=6e167b50c0e58b76f28a56e01b156c4b39672d51621d66bcfca631e52b5de55a"
    }
  },
  {
    "ts": null,
    "headline": "Novo shares rise for second day after Lilly obesity pills trails Wegovy in trial",
    "summary": "Investing.com - Copenhagen-listed shares of Novo Nordisk (CSE:NOVOb) rose by more than 5% on Friday, extending gains notched in the prior session, after a weight-loss pill from chief rival Eli Lilly (NYSE:LLY) showed less effectiveness than its blockbuster Wegovy drug.",
    "url": "https://finnhub.io/api/news?id=23a5595809edcb0a676e4538729fcca14ec2ea76e9656c57bafc056275aa95b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754646145,
      "headline": "Novo shares rise for second day after Lilly obesity pills trails Wegovy in trial",
      "id": 136266273,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com - Copenhagen-listed shares of Novo Nordisk (CSE:NOVOb) rose by more than 5% on Friday, extending gains notched in the prior session, after a weight-loss pill from chief rival Eli Lilly (NYSE:LLY) showed less effectiveness than its blockbuster Wegovy drug.",
      "url": "https://finnhub.io/api/news?id=23a5595809edcb0a676e4538729fcca14ec2ea76e9656c57bafc056275aa95b4"
    }
  },
  {
    "ts": null,
    "headline": "Why a Weight-Loss Pill Is Still a Big Deal",
    "summary": "Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.",
    "url": "https://finnhub.io/api/news?id=b7263a34bd1a671b3fff466bcb30d3ff51d8a17624b059a43eb53a082e7298a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754645400,
      "headline": "Why a Weight-Loss Pill Is Still a Big Deal",
      "id": 136266276,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.",
      "url": "https://finnhub.io/api/news?id=b7263a34bd1a671b3fff466bcb30d3ff51d8a17624b059a43eb53a082e7298a4"
    }
  },
  {
    "ts": null,
    "headline": "Heard on the Street Thursday Recap: Apple Keeps the Tariffs Away",
    "summary": "Apple stock rallied for a second day after President Trump said the iPhone maker and other companies that are investing in U.S. manufacturing could avoid 100% chip tariffs.  Apple's shares rose 3.2% on Thursday, adding more than $100 billion in market capitalization.  Trump's announcement raises many questions.",
    "url": "https://finnhub.io/api/news?id=de79789f61c943724ae7272ec1ceb22e448593181c58666e62855d97943a3fbf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754638680,
      "headline": "Heard on the Street Thursday Recap: Apple Keeps the Tariffs Away",
      "id": 136266277,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Apple stock rallied for a second day after President Trump said the iPhone maker and other companies that are investing in U.S. manufacturing could avoid 100% chip tariffs.  Apple's shares rose 3.2% on Thursday, adding more than $100 billion in market capitalization.  Trump's announcement raises many questions.",
      "url": "https://finnhub.io/api/news?id=de79789f61c943724ae7272ec1ceb22e448593181c58666e62855d97943a3fbf"
    }
  }
]